Chapter 7: Idiopathic membranous nephropathy

Kidney International Supplements

Volumn 2, Issue 2, 2012, Pages 186-197

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85096618679     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2012.20     Document Type: Article

References (115)

1. Gipson, D.S., Trachtman, H., Kaskel, F.J., et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 80 (2011), 868–878.
2. Abe, S., Amagasaki, Y., Konishi, K., et al. Idiopathic membranous glomerulonephritis: aspects of geographical differences. J Clin Pathol 39 (1986), 1193–1198.
3. Cahen, R., Francois, B., Trolliet, P., et al. Aetiology of membranous glomerulonephritis: a prospective study of 82 adult patients. Nephrol Dial Transplant 4 (1989), 172–180.
4. Schwartz, M.M., Membranous glomerulonephritis. Heptinstall's Pathology of the Kidney, 2007, Lippincott Williams & Wilkins, Philadelphia, PA, 205–251 In: Jennette JC, Olson JL, Schwartz MM (eds)., 6th edn, vol. 1.
5. Kuroki, A., Shibata, T., Honda, H., et al. Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. Intern Med 41 (2002), 936–942.
6. Ohtani, H., Wakui, H., Komatsuda, A., et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant 19 (2004), 574–579.
7. Zeng, C.H., Chen, H.M., Wang, R.S., et al. Etiology and clinical characteristics of membranous nephropathy in Chinese patients. Am J Kidney Dis 52 (2008), 691–698.
8. Honkanen, E., Survival in idiopathic membranous glomerulonephritis. Clin Nephrol 25 (1986), 122–128.
9. Ehrenreich, T., Porush, J.G., Churg, J., et al. Treatment of idiopathic membranous nephropathy. N Engl J Med 295 (1976), 741–746.
10. Lefaucheur, C., Stengel, B., Nochy, D., et al. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int 70 (2006), 1510–1517.
11. Beck, L.H. Jr, Bonegio, R.G., Lambeau, G., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361 (2009), 11–21.
12. Glassock, R.J., Secondary membranous glomerulonephritis. Nephrol Dial Transplant 7:Suppl 1 (1992), 64–71.
13. Gluck, M.C., Gallo, G., Lowenstein, J., et al. Membranous glomerulonephritis. Evolution of clinical and pathologic features. Ann Intern Med 78 (1973), 1–12.
14. Burstein, D.M., Korbet, S.M., Schwartz, M.M., Membranous glomerulonephritis and malignancy. Am J Kidney Dis 22 (1993), 5–10.
15. Jha, V., Ganguli, A., Saha, T.K., et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18 (2007), 1899–1904.
16. Passerini, P., Ponticelli, C., Membranous nephropathy. Treatment of Primary Glomerulonephritis, 2009, Oxford University Press, Oxford, UK, 261–312 In: Ponticelli C, Glassock R (eds)., 2nd edn.
17. Glassock, R.J., Diagnosis and natural course of membranous nephropathy. Semin Nephrol 23 (2003), 324–332.
18. Cameron, J.S., Membranous nephropathy and its treatment. Nephrol Dial Transplant 7:Suppl 1 (1992), 72–79.
19. Cattran, D.C., Idiopathic membranous glomerulonephritis. Kidney Int 59 (2001), 1983–1994.
20. Donadio, J.V. Jr, Torres, V.E., Velosa, J.A., et al. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int 33 (1988), 708–715.
21. Erwin, D.T., Donadio, J.V. Jr, Holley, K.E., The clinical course of idiopathic membranous nephropathy. Mayo Clin Proc 48 (1973), 697–712.
22. Hopper, J. Jr, Trew, P.A., Biava, C.G., Membranous nephropathy: its relative benignity in women. Nephron 29 (1981), 18–24.
23. Murphy, B.F., Fairley, K.F., Kincaid-Smith, P.S., Idiopathic membranous glomerulonephritis: long-term follow-up in 139 cases. Clin Nephrol 30 (1988), 175–181.
24. Row, P.G., Cameron, J.S., Turner, D.R., et al. Membranous nephropathy. Long-term follow-up and association with neoplasia. Q J Med 44 (1975), 207–239.
25. Schieppati, A., Mosconi, L., Perna, A., et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329 (1993), 85–89.
26. Polanco, N., Gutierrez, E., Covarsi, A., et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21 (2010), 697–704.
27. Cattran, D., Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol 16 (2005), 1188–1194.
28. Cattran, D.C., Reich, H.N., Beanlands, H.J., et al. The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 23 (2008), 2247–2253.
29. Pei, Y., Cattran, D., Greenwood, C., Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 42 (1992), 960–966.
30. Cattran, D.C., Pei, Y., Greenwood, C.M., et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 51 (1997), 901–907.
31. Fervenza, F.C., Sethi, S., Specks, U., Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol 3 (2008), 905–919.
32. Laluck, B.J. Jr, Cattran, D.C., Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am J Kidney Dis 33 (1999), 1026–1032.
33. Troyanov, S., Wall, C.A., Miller, J.A., et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 66 (2004), 1199–1205.
34. Kosmadakis, G., Filiopoulos, V., Georgoulias, C., et al. Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome. Scand J Urol Nephrol 44 (2010), 251–256.
35. Reichert, L.J., Koene, R.A., Wetzels, J.F., Urinary excretion of beta 2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy. J Am Soc Nephrol 6 (1995), 1666–1669.
36. Reichert, L.J., Koene, R.A., Wetzels, J.F., Urinary IgG excretion as a prognostic factor in idiopathic membranous nephropathy. Clin Nephrol 48 (1997), 79–84.
37. Donadio, J.V. Jr, Holley, K.E., Anderson, C.F., et al. Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. Kidney Int 6 (1974), 431–439.
38. Murphy, B.F., McDonald, I., Fairley, K.F., et al. Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis. Clin Nephrol 37 (1992), 229–234.
39. Shearman, J.D., Yin, Z.G., Aarons, I., et al. The effect of treatment with prednisolone or cyclophosphamide-warfarin-dipyridamole combination on the outcome of patients with membranous nephropathy. Clin Nephrol 30 (1988), 320–329.
40. Ponticelli, C., Zucchelli, P., Imbasciati, E., et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 310 (1984), 946–950.
41. Falk, R.J., Hogan, S.L., Muller, K.E., et al. Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. Ann Intern Med 116 (1992), 438–445.
42. McQuarrie, E.P., Stirling, C.M., Geddes, C.C., Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy. Nephrol Dial Transplant 27 (2012), 235–242.
43. Ponticelli, C., Zucchelli, P., Passerini, P., et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320 (1989), 8–13.
44. Ponticelli, C., Zucchelli, P., Passerini, P., et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 48 (1995), 1600–1604.
45. Ponticelli, C., Zucchelli, P., Passerini, P., et al. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N Engl J Med 327 (1992), 599–603.
46. Ponticelli, C., Altieri, P., Scolari, F., et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9 (1998), 444–450.
47. Hogan, S.L., Muller, K.E., Jennette, J.C., et al. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 25 (1995), 862–875.
48. Imperiale, T.F., Goldfarb, S., Berns, J.S., Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials. J Am Soc Nephrol 5 (1995), 1553–1558.
49. Jindal, K., West, M., Bear, R., et al. Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. Am J Kidney Dis 19 (1992), 61–67.
50. Perna, A., Schieppati, A., Zamora, J., et al. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 44 (2004), 385–401.
51. West, M.L., Jindal, K.K., Bear, R.A., et al. A controlled trial of cyclophosphamide in patients with membranous glomerulonephritis. Kidney Int 32 (1987), 579–584.
52. Hofstra, J.M., Branten, A.J., Wirtz, J.J., et al. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. Nephrol Dial Transplant 25 (2010), 129–136.
53. Branten, A.J., Reichert, L.J., Koene, R.A., et al. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. QJM 91 (1998), 359–366.
54. du Buf-Vereijken, P.W., Branten, A.J., Wetzels, J.F., Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol Dial Transplant 19 (2004), 1142–1148.
55. Controlled trial of azathioprine and prednisone in chronic renal disease. Report by Medical Research Council Working Party. Br Med J 2 (1971), 239–241.
56. Controlled trial of azathioprine in the nephrotic syndrome secondary to idiopathic membranous glomerulonephritis. Can Med Assoc J 115 (1976), 1209–1210.
57. Lagrue, G., Bernard, D., Bariety, J., et al. [Treatment with chlorambucil and azathioprine in primary glomerulonephritis. Results of a ‘controlled’ study]. J Urol Nephrol (Paris) 81 (1975), 655–672.
58. Ambalavanan, S., Fauvel, J.P., Sibley, R.K., et al. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J Am Soc Nephrol 7 (1996), 290–298.
59. Guasch, A., Suranyi, M., Newton, L., et al. Short-term responsiveness of membranous glomerulopathy to cyclosporine. Am J Kidney Dis 20 (1992), 472–481.
60. Cattran, D.C., Appel, G.B., Hebert, L.A., et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 59 (2001), 1484–1490.
61. Alexopoulos, E., Papagianni, A., Tsamelashvili, M., et al. Induction and long-term treatment with cyclospiorin A in membranous glomerulonephritis with the nephrotic syndrome (abstract). J Am Soc Nephrol, 16, 2005, 780A.
62. Cattran, D.C., Greenwood, C., Ritchie, S., et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 47 (1995), 1130–1135.
63. DeSanto, N.G., Capodicasa, G., Giordano, C., Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporin. Am J Nephrol 7 (1987), 74–76.
64. Rostoker, G., Belghiti, D., Ben Maadi, A., et al. Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron 63 (1993), 335–341.
65. Praga, M., Barrio, V., Juarez, G.F., et al. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 71 (2007), 924–930.
66. Bruns, F.J., Adler, S., Fraley, D.S., et al. Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone. Ann Intern Med 114 (1991), 725–730.
67. Mathieson, P.W., Turner, A.N., Maidment, C.G., et al. Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet 2 (1988), 869–872.
68. Torres, A., Dominguez-Gil, B., Carreno, A., et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int 61 (2002), 219–227.
69. Warwick, G.L., Geddes, C.G., Boulton-Jones, J.M., Prednisolone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure. Q J Med 87 (1994), 223–229.
70. Chen, M., Li, H., Li, X.Y., et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci 339 (2010), 233–238.
71. A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. N Engl J Med 301 (1979), 1301–1306.
72. Cattran, D.C., Delmore, T., Roscoe, J., et al. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 320 (1989), 210–215.
73. Shiiki, H., Saito, T., Nishitani, Y., et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int 65 (2004), 1400–1407.
74. Branten, A.J., du Buf-Vereijken, P.W., Vervloet, M., et al. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 50 (2007), 248–256.
75. Chan, T.M., Lin, A.W., Tang, S.C., et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton) 12 (2007), 576–581.
76. Senthil Nayagam, L., Ganguli, A., Rathi, M., et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant 23 (2008), 1926–1930.
77. Dussol, B., Morange, S., Burtey, S., et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis 52 (2008), 699–705.
78. Remuzzi, G., Chiurchiu, C., Abbate, M., et al. Rituximab for idiopathic membranous nephropathy. Lancet 360 (2002), 923–924.
79. Ruggenenti, P., Chiurchiu, C., Brusegan, V., et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 14 (2003), 1851–1857.
80. Ruggenenti, P., Chiurchiu, C., Abbate, M., et al. Rituximab for idiopathic membranous nephropathy: who can benefit?. Clin J Am Soc Nephrol 1 (2006), 738–748.
81. Fervenza, F.C., Cosio, F.G., Erickson, S.B., et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73 (2008), 117–125.
82. Cravedi, P., Ruggenenti, P., Sghirlanzoni, M.C., et al. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2 (2007), 932–937.
83. Fervenza, F.C., Abraham, R.S., Erickson, S.B., et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 5 (2010), 2188–2198.
84. Berg, A.L., Arnadottir, M., ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol Dial Transplant 19 (2004), 1305–1307.
85. Berg, A.L., Nilsson-Ehle, P., Arnadottir, M., Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int 56 (1999), 1534–1543.
86. Ponticelli, C., Passerini, P., Salvadori, M., et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 47 (2006), 233–240.
87. Ahmed, S., Rahman, M., Alam, M.R., et al. Methyl prednisolone plus chlorambucil as compared with prednisolone alone for the treatment of idiopathic membranous nephropathy. A preliminary study. Bangladesh Renal J 13 (1994), 51–54.
88. Reichert, L.J., Huysmans, F.T., Assmann, K., et al. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann Intern Med 121 (1994), 328–333.
89. Bomback, A.S., Derebail, V.K., McGregor, J.G., et al. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 4 (2009), 734–744.
90. Nasr, S.H., Said, S.M., Valeri, A.M., et al. Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. Clin J Am Soc Nephrol 4 (2009), 299–308.
91. Troxell, M.L., Saxena, A.B., Kambham, N., Concurrent anti-glomerular basement membrane disease and membranous glomerulonephritis: a case report and literature review. Clin Nephrol 66 (2006), 120–127.
92. Waldman, M., Austin, H.A. III, Controversies in the treatment of idiopathic membranous nephropathy. Nat Rev Nephrol 5 (2009), 469–479.
93. Ponticelli, C., Passerini, P., Altieri, P., et al. Remissions and relapses in idiopathic membranous nephropathy. Nephrol Dial Transplant 7:Suppl 1 (1992), 85–90.
94. Suki, W.N., Trimarchi, H., Frommer, J.P., Relapsing membranous nephropathy. Response to therapy of relapses compared to that of the original disease. Am J Nephrol 19 (1999), 474–479.
95. du Buf-Vereijken, P.W., Wetzels, J.F., Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity. Nephrol Dial Transplant 19 (2004), 2036–2043.
96. Faurschou, M., Sorensen, I.J., Mellemkjaer, L., et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35 (2008), 100–105.
97. Segarra, A., Praga, M., Ramos, N., et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 4 (2009), 1083–1088.
98. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 13 (1978), 159–165.
99. USRDS 2008, Annual data report: Atlas of chronic kidney disease, Atlas of end-stage renal disease., 2008, US Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
100. Menon, S., Valentini, R.P., Membranous nephropathy in children: clinical presentation and therapeutic approach. Pediatr Nephrol 25 (2010), 1419–1428.
101. Makker, S.P., Treatment of membranous nephropathy in children. Semin Nephrol 23 (2003), 379–385.
102. Watson, A.R., Rance, C.P., Bain, J., Long term effects of cyclophosphamide on testicular function. Br Med J (Clin Res Ed) 291 (1985), 1457–1460.
103. Habib, R., Kleinknecht, C., Gubler, M.C., Extramembranous glomerulonephritis in children: report of 50 cases. J Pediatr 82 (1973), 754–766.
104. Olbing, H., Greifer, I., Bennett, B.P., et al. Idiopathic membranous nephropathy in children. Kidney Int 3 (1973), 381–390.
105. Chan, W.C., Tsao, Y.C., Diffuse membranous glomerulonephritis in children. J Clin Pathol 19 (1966), 464–469.
106. Trainin, E.B., Boichis, H., Spitzer, A., et al. Idiopathic membranous nephropathy. Clinical course in children. N Y State J Med 76 (1976), 357–360.
107. Latham, P., Poucell, S., Koresaar, A., et al. Idiopathic membranous glomerulopathy in Canadian children: a clinicopathologic study. J Pediatr 101 (1982), 682–685.
108. Ramirez, F., Brouhard, B.H., Travis, L.B., et al. Idiopathic membranous nephropathy in children. J Pediatr 101 (1982), 677–681.
109. Tsukahara, H., Takahashi, Y., Yoshimoto, M., et al. Clinical course and outcome of idiopathic membranous nephropathy in Japanese children. Pediatr Nephrol 7 (1993), 387–391.
110. Lee, B.H., Cho, H.Y., Kang, H.G., et al. Idiopathic membranous nephropathy in children. Pediatr Nephrol 21 (2006), 1707–1715.
111. Chen, A., Frank, R., Vento, S., et al. Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome. BMC Nephrol, 8, 2007, 11.
112. Valentini, R.P., Mattoo, T.K., Kapur, G., et al. Membranous glomerulonephritis: treatment response and outcome in children. Pediatr Nephrol 24 (2009), 301–308.
113. Bellomo, R., Atkins, R.C., Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted?. Nephron 63 (1993), 249–254.
114. Glassock, R.J., Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol 18 (2007), 2221–2225.
115. Sarasin, F.P., Schifferli, J.A., Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 45 (1994), 578–585.